Tirzepatide

Tirzepatide (LY3298176) is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It simultaneously activates both incretin pathways, producing complementary effects on insulin secretion, glucagon suppression, gastric emptying, and appetite signalling.

Research has investigated Tirzepatide extensively for its metabolic effects, including improvements in glycaemic control, body weight reduction, and lipid profiles. As a dual agonist, it combines the insulin-sensitizing and appetite-suppressing properties of GLP-1 with the additional metabolic benefits attributed to GIP receptor activation, representing a meaningful advance over single-agonist approaches in metabolic research.